INDEVUS Interessante Kurs Chance - 500 Beiträge pro Seite

[Biotechspezialx]

-66 %
Das ist wohl ein wenig übertrieben....
Interessante Pipeline mit Produkten auf den Markt! Absolut Interessanter Kandidat"!

Kauf zu 1,40 $

NDEVUS PHARMA INC
(NasdaqGM: IDEV)


Last Trade: 1.39
Trade Time: 12:00PM ET
Change: Down - (66.10%)
Prev Close: 4.10
Open: 1.31
Bid: 1.39 x 155400
Ask: 1.40 x 6650

[OOY2]

Bin voll Deiner Meinung,hier kommt die Chance wieder.Bin mit 0,91Euro eingestiegen.Wir hören wieder.

[roofy]

die amis mal wieder !
bin bei 1,3$ rein
völlig übertrieben das ganze
60mio cash

stimme vollkommen zu

[Biotechspezialx]

Volumen:57,957,921



über 2 Drittel der Firma haben Ihren Besitzer gewechselt!


Selten so was verrücktes gesehen!

So etwas extrem überzogenes!

Ach so Nebido um das es ging wird von Bayer Schering Pharma mit großem Erfolg in Europa bereits vertrieben! Die Anforderung der FDA Sicherheitsstudie scheinen wohl noch ein paar Infos diesen Monat zu kommen!
Selten bin ich mal so gelassen erfreut über so ein netten Kauf Kandidaten!


Das Unternehmen verfügt über eine Reihe von Medikamenten auf dem Markt, einschließlich Sanctura für über aktiven Blase, und mehrere andere in der Pipeline

[grafbibi]

http://boerse.ard.de:80/content.jsp?key=dokument_294788&go=N…

[Bombenleger]

Indevus shares plunge on testosterone drug delay
Wednesday June 4, 7:47 pm ET
Indevus Pharmaceuticals shares nosedive on outlook for 2-year delay on testosterone drug


NEW YORK (AP) -- Shares of Indevus Pharmaceuticals Inc. plunged Wednesday after the company said its injectable testosterone drug candidate will face a regulatory delay of up to two years with the Food and Drug Administration because of safety concerns.
ADVERTISEMENT


The Lexington, Mass.-based company said it expects the FDA to formally request additional safety data on Nebido before considering it for approval. Indevus will likely have to perform another study on the drug to get that data.

The stock fell $2.84, or 69.3 percent, to $1.26. Shares hit $1.19 earlier in the session, reaching their lowest point in nearly six years.

Indevus said it plans to refile its application with the FDA in about 18 months, followed by a six-month review. The FDA is concerned about a reaction seen in one patient immediately following injection of the drug, which led to coughing episodes and shortness of breath. In rare cases, symptoms from amounts of the oily injectable solution entering the vascular system can include dizziness, flushing or fainting.

The drug, which treats male hypogonadism, in which the testicles fail to produce enough testosterone, is already approved in Europe. Indevus said safety concerns likely arose from post-marketing studies conducted in Europe.

"We are very surprised and disappointed by the position the FDA is taking regarding the safety profile of Nebido given the large European experience," Dr. Glenn L. Cooper, chairman and chief executive of Indevus, said in a statement. "Rare coughing reactions have been well-described in the European product labeling of Nebido."

The drug development industry has been facing more regulatory scrutiny by the FDA in the wake of calls for more safety oversight. The tougher regulatory atmosphere follows high-profile safety cases, including that of Merck & Co.'s painkiller Vioxx, which was eventually pulled from the market after researchers determined it doubled the risk of heart attack and stroke.

The debacle cost Merck $4.85 billion to settle up to 50,000 lawsuits over the painkiller.

Indevus expects the official request for more safety data from the FDA by June 27.

Soleil Securities Group analyst Matt Renna downgraded shares of Indevus to "Hold" from "Buy," saying the drug was a key component to any potential gains for the company's stock.

[roofy]

http://seekingalpha.com/article/80164-indevus-pharmaceutical…

hier ein guter artikel zum thema nebido
die phantasie bleibt in diesem wert
sollte die fda ein einsehen haben gehts steil bergauf
die frage ist ob das unternehmen die zwei jahre übersteht

[roofy]

auf diesem level ist indevus ein übernahmekandidat
ich glaube diess investment kann man sehr entspannt angehen

[roofy]

Hier eine Bayer-Mitteilung aus dem Jahr 2007!
Ich kanns nicht fassen!

Nebido®, eine intramuskuläre Depot-Formulierung von Testosteron-Undecanoat, kann für Männer eine sichere und wirksame medikamentöse Therapie mit hoher Zufriedenheit darstellen. An einer prospektiven, einarmigen Open-Label-Studie in 16 Zentren in Deutschland nahmen 96 hypogonadale Patienten mit einem Durchschnittsalter von 48,6 Jahren teil. Die Männer erhielten über einen durchschnittlichen Zeitraum von 63 Wochen 6 Nebido®-Injektionen. Die Ergebnisse zeigen, dass Nebido® nicht nur das Lipidprofil (Senkung von Gesamtcholesterin und LDL-Cholesterin) sowie die Glykämieregulierung (Blutzuckerspiegel) verbesserte, sondern auch eine Besserung der psychologischen, somatischen und sexuellen Symptome des Testosteronmangels bewirkte. Es gab keine klinisch relevanten Nebenwirkungen und 92,5 % der Patienten beurteilten die Behandlung mit Nebido® als sehr zufrieden stellend.

[Larry_1]

Antwort auf Beitrag Nr.: 34.240.800 von Biotechspezialx am 04.06.08 22:35:13

feine Sache, diese Aktie

bin gestern ebenfalls hier eingestiegen und versuche heute noch welche in USA zu bekommen (Limit 1,60 USD)

spannend

[Larry_1]

hmm,
hatte mir die Eröffnung in USA eigentlich anders vorgestellt

[Biotechspezialx]

Antwort auf Beitrag Nr.: 34.255.586 von Larry_1 am 06.06.08 16:09:17

Lehnt Dich entspannt zurück und schau dir das ganze noch mal in 3 Monaten in Deinem Depot an!

Diese Aktie hat dauerhaftes Potenzial.
5 Präparate auf dem Markt! + sehr gute Pipeline!!!

Habe das Down hier schon 3x mit gemacht die Erholung wird kommen .........GANZ SICHER!!!!
NUR ETWAS GEDULD::::::::::::

[Larry_1]

Antwort auf Beitrag Nr.: 34.258.128 von Biotechspezialx am 06.06.08 21:16:24

ja, Geduld habe ich schon gelernt

gestern, bei dem misserablem Gesamtmarkt, bei +/- Null geschlossen, ist schon mal nicht schlecht ---> das spricht auf jeden Fall für eine Erholung der Aktie.

Anm: habe z.Zt. noch ein paar andere Biowerte im Depot. Interessanterweise haben die gestern teilweise sogar im Plus geschlossen. ----> bestätigt das doch die Regel, das Biowerte sich vom Gesamtmarkt eigentlich gar nicht beeinflussen lassen.

Schönes Wochenende

[Larry_1]

wow, jetzt gehts aber up

[Biotechspezialx]

Antwort auf Beitrag Nr.: 34.311.555 von Larry_1 am 16.06.08 18:10:41

Denke das ich nicht zu viel versprochen hatte!!!
Selbst über 2$ noch immer noch lächerlich billig diese Biotech Papier
Sage nur 6 Produkte bereits auf dem Markt..........

[Larry_1]

Antwort auf Beitrag Nr.: 34.312.733 von Biotechspezialx am 16.06.08 22:14:56

ja, war ein Klasse Hinweis von Dir.

Ich mußte allerdings am Freitag eine Position schon wieder verkaufen, weil ich dringend die € benötigte

[Biotechspezialx]

Antwort auf Beitrag Nr.: 34.313.605 von Larry_1 am 17.06.08 08:48:27

Ist Schade solltest deine Position noch nicht aufgeben die nächsten 2-3 Monate geht hier noch einiges nach oben.....

[Larry_1]

Antwort auf Beitrag Nr.: 34.319.356 von Biotechspezialx am 17.06.08 20:04:24

Ich habe ja noch eine Position.
Gestern wieder superstarkes Volumen ---> die Aktie will weiter nach oben
Werde heute nochmals meinen Bestand erweitern
good time

[Biotechspezialx]

Indevus interessant (Global Biotech Investing)


Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" halten die Aktie von Indevus (ISIN US4540721093/ WKN 883147) für ein interessantes Investment.

Von Hochs um 8 USD im Herbst letzten Jahres seien die Titel von Indevus bis Anfang Juni wegen einer Verzögerung des potenziellen Top-Sellers Nebido auf Levels unter 1,50 USD in den Keller gegangen. Der fast sicher geglaubten Zulassung des in Europa bereits am Markt befindlichen Testosteron-Wirkstoffs habe die FDA vor zwei Wochen derb einen Riegel vorgeschoben. So fordere sie zusätzliche Sicherheitsdaten, die die Auflage einer neuen klinischen Studie erfordern würden. Dies koste nicht nur Zeit, sondern auch Geld, was Indevus nur begrenzt habe. Die UBS-Analysten würden "kaufen" mit Kursziel 12 USD sagen, bei aktuell 1,75 USD.

Mit dem Verziehen des Pulverdampfes könne es nach Ansicht der Experten von "Global Biotech Investing" aber bei Indevus in einigen Monaten schon ganz anders aussehen. (Ausgabe 12 vom 23. Juni 2008) (24.06.2008/ac/a/a) Analyse-Datum: 24.06.2008

Analyst: Global Biotech Investing
Rating des Analysten:


Quelle:aktiencheck.de

[hennep]

Habe IDEV schon längere Zeit auf meiner Watchlist...das war ja heute der Ritt auf der Rasierklinge........unglaublich ...und bin bei 1,15 Euro eingestiegen .........zu früh gefreut....25% plus bis auf 2,01$..und dann der Absturz....frage mich nur warum...wieso wird der Tittel runtergeputscht.....billiger reinkommen....eine Erklärung dafür....bei Labopharm ist das nicht passiert...bei geringem Volumen 45% plus....Hat jemand eine ERklärung dafür?

Gruß unbekannterweise

HENNEP

[Bombenleger]

Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Monday June 30, 10:21 am ET
Company Announces Revised Operating Plan to Respond to NEBIDO Delay


LEXINGTON, Mass., June 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV - News) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NEBIDO® related to a New Drug Application (NDA) submitted to the FDA in August 2007. The letter, received on June 27, 2008, indicated that the application may be approved if the Company is able to adequately respond to certain clinical deficiencies related to the product. The letter generally confirmed the Company's previously-announced indications from the FDA based on telephone discussions.
ADVERTISEMENT


The FDA has expressed a concern about a relatively small number of patients in European post-marketing use who have experienced respiratory symptoms immediately following the intramuscular injection of NEBIDO 1000 mg, 4 cc injection volume, (versus the 750 mg, 3 cc injection volume used in the United States). The Company believes and the FDA concurs that the reaction is likely the result of a small amount of the oily solution immediately entering the vascular system from the injection site, a known, rare complication of oil-based depot injections.

The phenomenon is characterized by short-term reactions involving an urge to cough, coughing episodes or a shortness of breath. In rare cases the reaction has been classified as serious or the patient experiences other symptoms such as dizziness, flushing or fainting. In the Company's U.S. clinical trials of NEBIDO 750 mg (3 cc injection volume), the proposed dose in the U.S., there was a single, mild, non-serious case of oil-based cough observed. In addition, the FDA believes that four cases in the European post-marketing experience may have an allergic, anaphylactoid component, although the Company believes these cases were improperly classified and represent the same oil-based phenomenon.

The FDA has requested the Company address these clinical deficiencies by providing detailed safety information from clinical studies to determine the precise incidence of serious post-injection oil-based reactions and allergic reactions. Specifically, the FDA has requested follow-up data from the on-going U.S. and European studies in which patients are being treated with NEBIDO on an extended basis. A majority of these trials are scheduled to be completed within twelve months. The FDA stated that depending on the findings, the number of subjects and the number of injections of testosterone undecanoate from the studies listed above, the safety database may need to include data from additional clinical studies. They have requested that the Company propose the size of the safety database (i.e., total number of subjects exposed to testosterone undecanoate intramuscular injection and total number of injections) and the rationale for the size of the proposed safety database.

FDA has also requested the Company provide a plan to minimize the risks associated with the clinical use of testosterone undecanoate intramuscular injection, namely, to reduce the incidence and/or severity of the serious oil-based reactions and has requested certain in vitro and skin-testing data to exclude an allergic component to the drug or some of its excipients.

Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus stated, "We believe that NEBIDO is a safe and effective drug for its intended use and continue to be disappointed that the FDA was not willing to approve the drug at this time with adequate labeling of the oil-based reactions and how to minimize them with proper injection technique. However, we are encouraged that this approvable letter provides a road map for the product's eventual approval. We will work with the FDA and our partner, Bayer Schering Pharma AG, to respond to the approvable letter and devise a plan to address the deficiencies. While the FDA has not specifically requested additional clinical studies, we believe that an additional study will likely be required to demonstrate that NEBIDO 750 mg (3 cc volume) administered with careful and proper intramuscular injection technique, has an acceptably low incidence of oil-based reactions to gain approval. In addition, we are pleased that FDA has provided guidance on how we can demonstrate that the product does not cause allergic reactions. We hope to be able to articulate a development plan to address FDA concerns within the next few months, and for now are maintaining our previous guidance that it may take the Company approximately 18 months to re-submit the revised NDA. We will communicate specific guidance on clinical plans and timelines when they are available."

Revised Operating Plan

In view of the NEBIDO regulatory delay, the Company's Board of Directors has approved a revised operating plan that more appropriately aligns the cost structure to the Company's revenue projections and development opportunities. The new operating plan provides for 1) aggressive support and top-line growth of marketed products, VANTAS® and SUPPRELIN® LA, 2) aggressive support for the launch of VALSTAR(TM) for bladder cancer later this year, 3) continued co-promotion with Allergan of SANCTURA® and SANCTURA XR(TM) with the urology sales force through March 2009, 4) initiation of Phase III trials for the six-month octreotide implant for acromegaly, and 5) significant reduction in operating expenses through a combination of headcount reductions of approximately 12 percent of employees, primarily at the corporate and administrative levels at the Lexington, Massachusetts headquarters, and reduction of other operating expenses.

Dr. Cooper said, "We have made the difficult but necessary decision to reduce the operating expenses and cash burn of the Company and intend to be vigilant in managing expenses through this difficult period. Under our revised plan, in fiscal 2009 we expect that our operating cash burn will fall to approximately $10 million per quarter on total revenues for the year of approximately $88 to $95 million. This is a significant improvement compared to our recent average operating cash burn of approximately $18 to $20 million per quarter and our expected revenues for fiscal 2008 of approximately $70 million. Our current revised plan does not give effect to additional NEBIDO studies as their size, duration and expense are not yet final. In conjunction with implementation of this revised operating plan, the Company anticipates recording an aggregate restructuring charge of approximately $3 to $4 million in the third fiscal quarter.

"While the NEBIDO delay is unfortunate, the Company remains strong and is committed to the patients and physicians who use and prescribe our products for urological and endocrine disorders. We are highly focused on driving revenue growth for our marketed products SANCTURA XR, VANTAS and SUPPRELIN LA and our organization is also preparing to launch VALSTAR, another important urology product, subject to FDA approval. In addition to NEBIDO, we are focused on our octreotide implant, a high-value Phase 3 product which we believe can reach the market, assuming approval, by the end of 2010. Also, we are actively exploring the acquisition of late-stage or marketed products which can further leverage our experienced urology and endocrinology field sales force.

"The Company is also moving forward to strengthen its balance sheet," continued Dr. Cooper. "In addition to potential out-licensing transactions for the Company's partnerable products, we are also exploring opportunities for the monetization of the royalties we receive from sales of SANCTURA and SANCTURA XR. Our financial goals are to secure adequate non-dilutive capital to fund the Company's operations for the foreseeable future and to retire the Company's outstanding convertible debt which matures in July 2009."

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA® and SANCTURA XR(TM) for overactive bladder, VANTAS® for advanced prostate cancer, SUPPRELIN® LA for central precocious puberty, and DELATESTRYL® to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO® for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly.

About NEBIDO

NEBIDO® is a long-acting depot preparation of testosterone undecanoate under development for the treatment of male hypogonadism. NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About VANTAS

VANTAS® is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. VANTAS is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any components in VANTAS.

About SUPPRELIN LA

SUPPRELIN® LA is a subcutaneous implant indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. It utilizes the HYDRON® Polymer Technology and is specifically designed to provide a continuous release over 12 months of the gonadotropin releasing hormone (GnRH) agonist, histrelin. SUPPRELIN LA is contraindicated in patients with hypersensitivity to GnRH or GnRH analogs.

About SANCTURA and SANCTURA XR

SANCTURA® and SANCTURA XR(TM) belong to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax detrusor smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or unstable detrusor muscle function is believed to be the cause of overactive bladder.

SANCTURA and SANCTURA XR possess a quaternary ammonium structure that may be instrumental in the low incidence of CNS side-effects. At therapeutic concentrations in vitro, SANCTURA does not interact with drugs metabolized by the Cytochrome P-450 system, a metabolic pathway commonly associated with drug-drug interactions, and the majority of the absorbed dose is excreted largely unchanged into the urine.

Patients who have urinary retention, gastric retention, uncontrolled narrow-angle glaucoma or hypersensitivity to SANCTURA should not use SANCTURA.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.


Contact:
For Indevus
Michael W. Rogers Brooke D. Wagner
Executive Vice President and CFO VP, Corporate Communications
[phone] [phone]




--------------------------------------------------------------------------------
Source: Indevus Pharmaceuticals, Inc.

[Biotechspezialx]

Ganz einfach zu Beantworten oder auch doch nicht!!!

Die FDA fordert nicht speziell einen neuen Sicherheitsgrad Test zu NEBIDO 750 mg / INDEVUS will aber einen Test um alle Unklarheiten beseitigen.
Einsparungen in der Verwaltung kamen gut an ---dagegen spricht wieder die lange Dauer so eines Test der viel Cash verbrennt.

Man ist hin und her gerissen von diesen Meldung und hat keine klare Linie, wie man das ganze, in welchem Licht betrachten soll.........

[hennep]

Antwort auf Beitrag Nr.: 34.416.811 von Biotechspezialx am 01.07.08 22:26:52

Hallo Erstmal........unbekannterweise.......,
die Zukunft sieht doch ganz gut aus,wenn Du Dir die Präperate die schon auf dem Markt sind anschaust,da sollen Sie halt den Test von Bayer anfordern in Europa ist das doch schon auf dem Markt oder täusche ich mich?
Ist für mich ne Langzeitgeschichte.....vielleicht übernimmt ja auch Bayer IDEV....so um 10$,das wäre doch was..oder?
was hälst Du denn von Labopharm (DDSS),da steht auch was in der Warteschlange zum August....wundert mich nur das Volumen so niedrig ist,und keine Shorter am Werke sind.
Die Prognosen sind gut und wenn die 10 millionen shares gecovert werden noch besser!
Wenn der Markt wieder dreht und sich wieder beruhigt hat,geht es auch schnell wieder über 2,50$ oder was meinst Du?

Gruß

HENNEP

[Biotechspezialx]

Antwort auf Beitrag Nr.: 34.416.961 von hennep am 01.07.08 22:51:58

INDEVUS steht nicht zum Verkauf! Eine friedliche Übernahme halte ich derzeit f. ausgeschlossen! CEO Cooper sieht die Markteinführung von Nebido als sein krönendes Abschluss Geschenk f. INDEVUS!

Der Mann verschiebt sogar seinen Ruhestand! Für mich einer der besten und Fähigsten CEO`S der Branche!!!

Auffällig da kann ich einem vor Poster nur recht geben das nach dem Kurssturz da jemand mächtig eingekauft hat im Hintergrund! Da Fonds eher vorsichtig nach Kurs stürzen sind und erst mal abwarten wie sich der Markt das ganze sondiert scheint da wohl jemand an mehr als " NUR" interessiert zu sein.
Wir standen 2x kurz vor einem Ausbruch über die 2 $ Marke.
Wir wurden jedes mal zurück gekauft...na was denkt Ihr wie so wohl ....??

Labopharm halte ich derzeit zu Risiko behaftet ... die Testreihe scheint nicht den gewünschten Primär Punkte getroffen zu haben... abwarten auf entsprechende Veröffentlichungen! Zur Zeit to Hot!!!

Weniger Risiko behaftet- NEOSE TECH INC (NasdaqGM: NTEC)
Billig ( was eine höhere Stückzahl zulässt) und Erhollungs- Potential was ich schon 2x nach oben mit gemacht habe..

Grüße Bio

[hennep]

Antwort auf Beitrag Nr.: 34.425.143 von Biotechspezialx am 02.07.08 21:12:42

Hallo BioSpezi..................:-)

Danke für Deine Einschätzung und Deiner Empfehlung über NTEC...!
Der Wert wurde ja ganz gut niedergeprügelt,habe mir den Chartverlauf angesehen und festgestellt,daß Ende 2004 der Wert mal bei 12 $ stand......nicht schlecht.....der Specht....ist momentan ein echtes Schnäppchen....gestern wieder ein cent zugelegt ....jemand hat ordentlich zugegriffen.....20:41 Uhr 2,3 Millionen Shares für 699.596 $........kommt da was.....?
Reboundwerte sind angesagt....mußt natürlich das nötige Kleingeld haben.....bin bei financials angagiert.....Etrade ist mein Favorit....habe aber sattes Minus....zu früh investiert.....Du weißt der Einstieg ist Alles.....glaube an den Rebound....Mobile Pro....und Hedgie ist auch eingestiegen...nur die naked shorter machen ET das Leben nicht leicht........überlege ob ich nicht in nächster Zeit mir mal für einen 1000 er NTEC ins Depot lege....find ich Klasse das Du gute Recherche betreibst über die Biotechwerte.....Guck Dir die Geschichte und den Chartverlauf von unserem DEutschen Wert an GPC......und den Kursverlauf....Die Suche nach der Perle..........kannst schnell einen Griff ins Klo machen....! Na ja die Vorzeichen für IDEV stehen gut...und die amerikanischen Börsenseiten wie Stocktiger.com haben Idev auf Ihrer Watchlist und wenn Du in die Chats gehst hörste eigentlich nur positive Stimmen.........bin zuversichtlich ...........:-)

Ich wünsche Allen Investierten einen schönen Tag....und danke Dir Spezi nochmal.......Tüss

Hennep

[Biotechspezialx]

Antwort auf Beitrag Nr.: 34.428.810 von hennep am 03.07.08 11:53:00

Ganz Intressanter Artikel..........

Biotech - Das Comeback einer gebeutelten Branche!?


Armin Brack, Chefredakteur


Lieber Geldanleger,

ich bin grundsätzlich überhaupt kein Freund von Biotechnologie als Anlage-Thema. Zu groß sind die Risiken von Rückschlägen bei der Produktentwicklung, zu fachspezifisch und komplex die Materie, als dass ein Nicht-Mediziner hier kompetente Einschätzungen abgeben könnte.

Trotzdem: Die relative Stärke und der gute Newflow zuletzt lassen aufhorchen. Warum Biotech wieder voll im Trend liegt und daher von Anlegern nicht ignoriert werden sollte.

Die Meldung der Übernahme des deutschen Biotech-Forschungsunternehmens Jerini durch die Briten Shire Pharmaceuticals ging fast ein wenig unter am späten Donnerstagmorgen. Zu sehr sind die Börsianer derzeit mit sich selbst und dem schwachen Gesamtmarkt beschäftigt.

Dabei ist es meiner Ansicht nach mehr als bemerkenswert, dass Shire für die Deutschen einen Preis von 330 Millionen Euro oder 6,25 Euro je Aktie bezahlt. Schließlich lag Jerini Ende April noch ausgezählt am Boden. Als die US-Arzneimittelbehörde FDA Icabitant dem Medikamentenkandidaten gegen hereditäre Angioödeme (Erbkrankheit mit schmerzhaften Hautschwellungen) die Zulassung verweigerte, sackte die Aktie auf unter einen Euro ab.

*Übernahme haucht neues Leben ein

Das Jammertal, in das die Biotech-Branche zumindest in Deutschland zusehends abgleitete, schien immer noch tiefer zu reichen. Zuvor hatten bereits Firmen wie GPC Biotech oder Paion die Anleger mit Flops bei Medikamentenkandidaten immer wieder enttäuscht.

Umgekehrt liegt aber natürlich in jeder Krise auch eine Chance. In diesem Fall sind es die stark zurück gekommenen Bewertungen. Nachdem der Quasi-Hilferuf der deutschen Biotech-Beteiligungsgesellschaft TVM Capital nach einer Übernahme in der Branche nun durch Shire erhört worden ist, wird deutlich, dass hier offenbar verborgene Werte zu heben sind.



MEIN FAZIT:

- Biotech ist wieder in. Die Übernahme von Jerini mit einem enormen Aufschlag auf den Aktienkurs vor der Übernahme, sollte auch anderen deutschen Unternehmen helfen.

- Die Bewertungen der Aktien hierzulande sind niedrig. Medigene ist ein interessanter Übernahmekandidat, aber als Forschungsunternehmen auch sehr spekulativ.

- In den USA gibt es bereits wieder verschiedene Biotech-Aktien in schönen Aufwärtstrend, die trotz schwachem Markt auf neue Jahreshochs gelaufen sind, unter anderen Sequenom.

- Biotech-/Pharma-Aktien sind kaum konjunkturabhängig und widersetzen sich daher aktuell dem Markttrend.

[gongolo]

Antwort auf Beitrag Nr.: 34.443.486 von Biotechspezialx am 05.07.08 10:42:22

War wohl doch nix??
Wie so oft.

[avant_immuno]

Antwort auf Beitrag Nr.: 34.700.618 von gongolo am 11.08.08 15:43:36

Good News nachbörslich von INDEVUS.

SQUEEEEZZZZZZZZEEEE

http://biz.yahoo.com/ap/080813/indevus_drug_patent.html?.v=1

Indevus says bladder treatment gets US patent
Wednesday August 13, 5:47 pm ET
Indevus Pharmaceuticals says overactive bladder treatment gets patent protection through 2025

[avant_immuno]

Antwort auf Beitrag Nr.: 34.723.644 von avant_immuno am 14.08.08 08:36:42

IDEV up 25%

[avant_immuno]

Antwort auf Beitrag Nr.: 34.726.561 von avant_immuno am 14.08.08 13:24:11

Verfolgt jemand INDEVUS? Dieser Wert scheint noch viel Potenzial zu haben......................

[Briefkastenomma]

Ich hab mich am Tage des Absturzes spontan eingedeckt und möchte mich beim Ersteller des Threads herzlich bedanken

Frage an die besser Informierten:
Ist schon absehbar, wann die nächsten wichtigen News zu Indevus kommen könnten und as glaubt ihr, wie es weitergeht?

[Larry_1]

Antwort auf Beitrag Nr.: 34.836.336 von Briefkastenomma am 24.08.08 17:08:38

heute geht es ganz gut weiter
aber leider ohne mich, habe Einstieg verpennt

[Biotechspezialx]

Antwort auf Beitrag Nr.: 34.836.336 von Briefkastenomma am 24.08.08 17:08:38

Denke das ich wieder nicht zu viel versprochen habe!

Gewinne mit nehmen!

[OOY2]

Ich bleib noch drin,hier läuft noch was ganz GROSSES

[Bikermichel]

Schön ruhig hier.

[Bikermichel]

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, (News) Inc. today announced the Company will be presenting at the Oppenheimer 19th Annual Healthcare Conference on Monday, November 3, 2008 at 8:40 AM Eastern Time. The Company will also be presenting at the Rodman&Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 9:30 AM Eastern Time. Both conferences are being held in New York City. The presentations will be web cast live and may be accessed by visiting the Investors section of the Indevus website at http://www.indevus.com/.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Michael W. Rogers Robin L. DeCarlo EVP and Chief Financial Officer Director, Corporate Communications [phone] [phone]

[Bikermichel]

Indevus Pharmaceuticals to Announce Fiscal 2008 Financial Results on Tuesday, November 25, 2008

LEXINGTON, Mass., Nov. 18 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, (News) Inc. will announce its fiscal 2008 financial results in a press release to be issued before market open on Tuesday, November 25, 2008. The Company will host a conference call and webcast to discuss these results at 9:00 AM eastern time on Tuesday, November 25, 2008.

The live call may be accessed by dialing 866-543-6403 from the U.S. and Canada, and 617-213-8896 from international locations. The participant passcode is 92405431. Investors are advised to dial into the call at least ten minutes prior to the call to register. A replay of the call will be available beginning at 11:00 AM on November 25, 2008 and lasting until 12:00 AM on December 23, 2008. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 49937348.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, http://www.indevus.com/. An archived version of the call will be accessible at the same web address for 30 days following the live call.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Michael W. Rogers Robin L. DeCarlo EVP and Chief Financial Officer Director, Corporate Communications [phone] [phone]

[Biotechspezialx]

Der Januar dürfte sehr Interessant hier werden!!!
Bis dahin könnte man den einen oder anderen schwachen Tag hier mal ausnutzen und sich überlegen ob man da ein wenig aufstockt.

[Bikermichel]

25.11.2008 13:41
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

LEXINGTON, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, (News) Inc. today announced its consolidated results of operations for the fiscal year and the three-month period ended September 30, 2008. The Company will host a conference call and webcast today beginning at 9:00 am eastern time (details follow below).

The Company reported fiscal 2008 consolidated revenues of $77.8 million, an increase of 18% from fiscal 2007 revenues of $66.1 million. For the three- month period ended September 30, 2008, the Company reported consolidated revenues of $23.3 million, a decrease of 21% from the $29.5 million reported for the three-month period ended September 30, 2007. The three-month period ended September 30, 2007 included a one-time, up-front recognition of $13.0 million related to the approval milestone for SANCTURA XR(TM) from Allergan.

For fiscal 2008, the Company reported a consolidated net loss of $65.6 million, or $0.86 per share, compared to a consolidated net loss of $103.8 million or $1.61 per share for fiscal 2007. Fiscal 2008 results include one- time restructuring charges of approximately $3.0 million. For the three-month period ended September 30, 2008, the Company reported a consolidated net loss of $14.0 million or $0.18 per share, compared to a consolidated net loss of $8.8 million or $0.12 per share for the three-month period ended September 30, 2007.

At September 30, 2008, the Company had consolidated cash, cash equivalents and marketable securities totaling approximately $131.3 million.

"Fiscal 2008 was extremely active for the Company," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The year ended on a very strong note and the Company is in excellent shape to have a successful coming year. In particular, we now have a clear path for the resubmission of our NDA for NEBIDO(R), our commercial products are performing extremely well in their respective markets, our late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million financing this summer gives us a strong balance sheet.

"After receiving an Approvable letter in June from the FDA on our NDA for NEBIDO, we began planning the course toward resubmission to address FDA's concerns about the quantification of the incidence of serious cough reactions in clinical trials. The NDA contained a single, serious cough reaction in approximately 4,000 injections of NEBIDO. In September, we reached agreement with FDA that submitting additional safety data from ongoing clinical trials in Europe would be appropriate and sufficient to address their concerns. The new data include the results from approximately 10,000 additional injections in Phase IV trials conducted by our partner, Bayer Schering Pharma AG, Germany. The data from these trials has been collected and we believe that there have been no additional cases of serious cough reaction implying an incidence of approximately 1 in 14,000 injections which we believe confirms the rarity of the adverse event. We expect to re-file the NDA by the end of the first calendar quarter of 2009, and FDA will have six months to review the NDA.

"We continue to see strong performance and positive trends for VANTAS(R) (prostate cancer) and SUPPRELIN(R) LA (central precocious puberty). Sales of VANTAS units in the fourth quarter were up 70% over the fourth quarter last year, and we are encouraged by the trends in the first quarter. VANTAS is the only once-yearly treatment in the market and our sales force has done a terrific job of demonstrating the benefits of a long acting product," continued Dr. Cooper.

"Adoption of SUPPRELIN LA in the treatment of central precocious puberty continues to exceed even our most optimistic forecasts. We launched SUPPRELIN LA in the third quarter of fiscal 2007. Our quarter over quarter revenue growth during our launch year has been quite strong with quarterly revenue increases averaging 25% in the last three fiscal quarters. We are now entering the initial phase of re-implants for existing patients. The market feedback on SUPPRELIN LA has been excellent, reinforcing the positive difference that a once-yearly implant (vs. monthly injections) has made in improving the lives of children with CPP and their families. We are very optimistic about the future of the product.

"Our R&D group is also quite active as we begin late stage clinical trials for two important products, octreotide and pagoclone. In October, we initiated our Phase III trial for our octreotide implant to treat acromegaly. The 140-patient pharmacokinetic study will compare the six-month octreotide implant to the current standard of care, Sandostatin(R) LAR(R) (monthly injections). We are optimistic about the prospects and benefits for the octreotide implant in this market, which currently exceeds $1.0 billion.

"In September, we completed a partnership agreement with Teva for the development and marketing of pagoclone for the treatment of stuttering. In the first calendar quarter of 2009, the companies expect to begin a 300- patient, six-month Phase IIb study. As per our agreement with Teva, this trial will be conducted by Indevus and funded by Teva. The results of this trial promise to be an important milestone in the development of pagoclone.

"We continue to look forward to the launch of VALSTAR(TM), our product for bladder cancer. We are awaiting plant inspections of our third-party manufacturer and hope to launch VALSTAR in the new year. VALSTAR is the only product currently approved for use in BCG-refractory bladder cancer patients who are not candidates for bladder removal.

"Fiscal 2008 was also an active and successful year for our Business Development group. In addition to the significant partnership completed with Teva, we also licensed rights outside of the United States for two of our core products. In April, we announced the licensing of European rights for VANTAS to Orion. VANTAS is pending final approval in Europe and it is expected to be launched by Orion in the first half of 2009. In May, we completed the license of Canadian rights for SANCTURA XR(TM) to Allergan.

"In addition, we successfully completed a $105 million non-recourse financing by monetizing a portion of the SANCTURA(R) franchise royalties. This non-recourse financing provides the Company sufficient capital to retire its outstanding Convertible Notes and to fund the Company into 2010. The Company now has the capital to get through several important milestones, including the expected FDA action date on NEBIDO, the results of our Phase III trial for octreotide, and the results of two Phase III trials for PRO 2000. In addition, we are optimistic that our ongoing discussions on the partnering front will contribute additional non-dilutive capital to the Company during the course of the coming year," concluded Dr. Cooper.

Recent Highlights

During the past year, the Company achieved a number of important milestones, including:

Clinical Development -- Results From NEBIDO Phase III Trial Shows 94 Percent of Men Maintained Normal Testosterone Levels Throughout Treatment -- Results From Two-Year Study Confirming SUPPRELIN LA Implant Maintains Profound Suppression of Hormones in Children with Premature Onset Puberty -- Completion of Enrollment in Phase III Trial of PRO 2000 -- Phase III Clinical Trial of Octreotide Implant for Acromegaly Initiated Business Development -- Licensing of European Rights for VANTAS to Orion Corporation -- Licensing of Canadian Rights for SANCTURA XR to Allergan -- Licensing of Worldwide Rights for Pagoclone to Teva Corporate -- Issuance of U.S. Patent for SANCTURA XR -- Completion of Private Placement of $105 Million of Non-Recourse Notes Financial Results

Total consolidated revenues for fiscal 2008 were $77.8 million, an increase of 18% from the $66.1 million reported for fiscal 2007. The primary components of revenue for fiscal 2008 were $43.8 million from the SANCTURA franchise, $16.6 million from sales of VANTAS, $13.2 million from sales of SUPPRELIN LA and $1.9 million from sales of DELATESTRYL(R).

Cost of product revenue for fiscal 2008 was $30.8 million, an increase of 111% from the $14.6 million reported for fiscal 2007. Cost of product revenue relates primarily of the costs to produce SANCTURA XR and royalty payments to Madaus and Supernus, all of which are reimbursed by Allergan, as well as the cost of product related to the sale of VANTAS, SUPPRELIN LA and DELATESTRYL.

Research and development expenses for fiscal 2008 were $25.0 million, a decrease of 40% from the $41.9 million reported for fiscal 2007. Marketing, general and administrative expenses for fiscal 2008 were $75.9 million, an increase of 26% from the $60.2 million reported for fiscal 2007.

Interest expense of $9.0 million for fiscal 2008 related to the Company's Convertible Notes and Non-recourse Notes.

Revenue for the quarter ended September 30, 2008 was $23.3 million, a decrease of 21% from the $29.5 million reported for the quarter ended September 30, 2007. The primary components of revenue for the quarter ended September 30, 2008 were $12.9 million from the SANCTURA franchise received from the Company's partner, $5.1 million from sales of VANTAS, $4.4 million from sales of SUPPRELIN LA, and $385,000 from sales of DELATESTRYL. The three- month period ended September 30, 2007 included a one-time, up-front recognition of $13.0 million related to the approval milestone for SANCTURA XR from Allergan.

Cost of product revenue for the quarter ended September 30, 2008 was $10.7 million, an increase of 91% from the $5.6 million reported for the quarter ended September 30, 2007. Cost of product revenue relates primarily to sales of SANCTURA and SANCTURA XR to Allergan at cost, royalties on sales of SANCTURA and SANCTURA XR that are reimbursed by Allergan, and costs associated with VANTAS, SUPPRELIN LA and DELATESTRYL.

Research and development expenses for the quarter ended September 30, 2008 were $7.1 million, a decrease of 43% from the $12.4 million reported for the quarter ended September 30, 2007. Marketing, general and administrative expenses for the quarter ended September 30, 2008 were $16.2 million, a decrease of 13% from the $18.7 million reported for the quarter ended September 30, 2007.

Conference call and webcast

The live call may be accessed by dialing 866-543-6403 from the U.S. and Canada, and 617-213-8896 from international locations. The participant passcode is 92405431. Investors are advised to dial into the call at least ten minutes prior to the call to register. A replay of the call will be available beginning at 11:00 AM on November 25, 2008 and lasting until 12:00 AM on December 23, 2008. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 49937348.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, http://www.indevus.com/. An archived version of the call will be accessible at the same web address for 30 days following the live call.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.

About SANCTURA and SANCTURA XR

SANCTURA(R) and SANCTURA(R) XR belong to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax detrusor smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or unstable detrusor muscle function is believed to be the cause of overactive bladder.

SANCTURA and SANCTURA XR possess a quaternary ammonium structure that may be instrumental in the low incidence of CNS side-effects. At therapeutic concentrations in vitro, SANCTURA does not interact with drugs metabolized by the Cytochrome P-450 system, a metabolic pathway commonly associated with drug-drug interactions, and the majority of the absorbed dose is excreted largely unchanged into the urine.

Patients who have urinary retention, gastric retention, uncontrolled narrow-angle glaucoma or hypersensitivity to SANCTURA should not use SANCTURA.

About DELATESTRYL

DELATESTRYL(R) is an injectable testosterone preparation for the treatment of male hypogonadism. DELATESTRYL is contraindicated in men with carcinomas of the breast or with known, or suspected, carcinomas of the prostate.

About VANTAS VANTAS(R) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. VANTAS is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any components in VANTAS.

About SUPPRELIN LA

SUPPRELIN(R) LA is a subcutaneous implant indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. It utilizes the hydron implant technology and is specifically designed to provide a continuous release over 12 months of the gonadotropin releasing hormone (GnRH) agonist, histrelin. SUPPRELIN LA is contraindicated in patients with hypersensitivity to GnRH or GnRH analogs.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R), VANTAS(R) and SUPPRELIN(R) LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR(R); reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Michael W. Rogers Robin L. DeCarlo EVP and Chief Financial Officer Director, Corporate Communications [phone] [phone] INDEVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the three and twelve months ended September 30, 2008 and 2007 (Amounts in thousands except per share data) For the three For the twelve months ended months ended September 30, September 30, 2008 2007 2008 2007 Total revenues $23,330 $29,467 $77,791 $66,067 Costs and expenses: Cost of product revenues 10,730 5,607 30,835 14,640 Research and development 7,097 12,433 24,964 41,927 Marketing, general and administrative 16,155 18,740 75,854 60,185 Acquired in-process research and development - - - 50,000 Amortization of intangibles 637 496 2,267 910 Restructuring Charge (549) - 2,980 - Total costs and expenses 34,070 37,276 136,900 167,662 Loss from operations (10,740) (7,809) (59,109) (101,595) Investment income 532 763 2,692 3,354 Interest expense (3,595) (1,614) (8,958) (5,492) Minority interest and other (175) (93) (175) (93) Net loss $(13,978) $(8,753) $(65,551) $(103,826) Net loss per common share: Basic and diluted $(0.18) $(0.12) $(0.86) $(1.61) Weighted average common shares: Basic and diluted 77,076 75,900 76,565 64,679 INDEVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) September 30, September 30, 2008 2007 Cash, cash equivalents $131,306 $71,142 Restricted cash 10,000 - Goodwill 48,244 48,244 Intangible assets, net 30,855 29,190 Other assets 42,597 34,474 Total assets $263,002 $183,050 Convertible notes $70,187 $68,112 Non-recourse notes 105,000 - Deferred revenue 189,015 158,461 Other liabilities 28,987 30,815 Capital 511,866 502,163 Accumulated deficit (642,053) (576,501) Total stockholders' deficit (130,187) (74,338) Total liabilities and stockholders' deficit $263,002 $183,050

[OOY2]

Ich hatte ja angekündigt,hier läuft noch was ganz Grosses. Der erste
Schritt ist bereits da.Wir werden an dieser Aktie noch viel Freude haben.

[Bikermichel]

Na , wenn das kein gutes Zeichen ist!

15:30:09 3,00 267.820 Stck.

Gruß Michel

[Bikermichel]

Antwort auf Beitrag Nr.: 36.241.364 von Bikermichel am 19.12.08 18:47:00

Symbol Euro € Wechselkurs US Dollar Geldkurs Briefkurs
EURUSD=X 2,07 2 Jan 1,3948 2,8872 1,3948 1,3950


Was bieten die den Leuten hier in Germany für
Verkaufskurse an.Lächerlich

[Biotechspezialx]

So jetzt bin ich gespannt!

Kommt Top-Sellers Nebido ! Der Kurs zeigt es schon an was man vermutet! Wir sollte in den nächsten Wochen einiges gehen!

[Bikermichel]

Irgend was ist hier im Busche.
Oh ja,das wäre schön

[Biotechspezialx]

Antwort auf Beitrag Nr.: 36.295.742 von Bikermichel am 02.01.09 22:29:26

Es steht die Enscheidung der FDA zu Nebido an!

[Bikermichel]

Chartanalyse (Quelle: Trading Central)
Kurzfristige(kfr.) Meinung: Kauf
Mittelfristige(mfr.) Meinung: Kauf
Veränderung
kfr.: Veränderung
mfr.:
Unterstützung: 2.08 / 2.5 / 2.67 Widerstand: 3.7 / 3.98 / 4.26

Unser Pivot-Punkt liegt bei 2.5.
Unsere Meinung: solange die Unterstützung bei 2.5 hält, ist die Aufwärtstendenz intakt.
Alternatives Szenario: ein Fall unter 2.5 würde einen weiteren Rückgang auf 1.83 auslösen
Analyse: der RSI liegt über 70. Das kann bedeuten, dass sich die Aktie entweder in einem anhaltenden Aufwärtstrend befindet oder dass sie überkauft ist und deshalb korrigieren wird (in diesem Fall auf bearishe Divergenzen achten). Der MACD liegt über der Signallinie und ist positiv. Die Konfiguration ist positiv. Es wird darauf hingewiesen, dass die Volumina seit einigen Tagen fallen.

Hm,ist nur eine Meinung schon klar.
Wenn Nebido kommt,kommen wir ganz schnell wieder in ganz andere Kursregionen.
Und die Chancen stehen meiner Meinung garnicht schlecht.

[StaatsKnecht]

Antwort auf Beitrag Nr.: 36.304.287 von Bikermichel am 05.01.09 12:05:34

http://finance.yahoo.com/news/Indevus-shares-jump-on-apf-136…

Shares of Indevus Pharmaceuticals Inc. gained ground Tuesday after the company said it would resubmit an application for approval of its developing horomonal treatment Nebido by the end of March, with seemingly better safety data. <<< Und wenn das erledigt ist dann >>

After resubmitting the application, the FDA will have six months to review the data. << kommt das noch dazu ,also ist vor ende 2009 nix bzgl Nebido zu erwarten .

Außerdem glaube ich kaum das Nebido ein kassenschlager wird .
Wieso ?? Ganz einfach ..

1. Soviel ich weiß kostet die behandlung rund 2400$ im Jahr << viel zu teuer
2. Es handelt sich um Injektionen warum sollte ich mir sowas spritzen lassen wenn es auch Gels gibt die erstens viel billiger sind und zweitens nicht weh tun.

Insgesamt ist IDEV naja OK .Schulnote 4

Tortzdem viel Erfolg an alle Investierten .

[die_Mitte]

Antwort auf Beitrag Nr.: 36.304.287 von Bikermichel am 05.01.09 12:05:34

hi
denke , dies jahr ist bei 4,50$ erst mal pause.
wann sind ergebnisse zu pro200 zu erwarten?
dies könnte natürlich alles über den haufen werfen.
im (hoffentlich) positiven sinne oder auch negativ.
aber das kennen wir ja.
bin am 5.6. zu €0,93 wieder rein.

viel glück allen.

[StaatsKnecht]

Idev wird von Endo übernommen

http://biz.yahoo.com/prnews/090105/ne55327.html?.v=1

[Bikermichel]

Antwort auf Beitrag Nr.: 36.241.364 von Bikermichel am 19.12.08 18:47:00

Ja und genau danach sieht der Kauf auch aus.Bin mir sicher das hier natürlich wieder einige mehr wußten.

Ganz schnell wieder in andere Kursregionen!
Mit Insiderwissen kannst du einen haufen Geld verdienen.Muß sagen das nervt mich ein wenig.

Aber was soll`s Kurssteigerung ist alles was zählt.
Muß mir alles noch mal in aller Ruhe durchlesen.

Company to Host Conference Call January 6, 2009 at 8:30 a.m. EST

LEXINGTON, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that it has entered into a definitive merger agreement under which Endo Pharmaceuticals Holdings, Inc. will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain milestones related to NEBIDO (R) (in development for hypogonadism) and the octreotide implant (in development for acromegaly and carcinoid syndrome), two of Indevus' primary product candidates. The up-front consideration of $4.50 per share represents a premium of 45.2% over today's closing price of the common stock of Indevus, and a 59.0% premium over the 30-day volume weighted average price for the common stock. The transaction has been approved by the boards of directors of both companies. The Company will host a conference call and webcast on January 6, 2009 beginning at 8:30 am Eastern time (details follow below).

"For many reasons, we are very pleased to bring this transaction to the shareholders and other stakeholders of the Company," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "For our shareholders, the deal not only captures a significant premium in the up-front portion of the consideration, but our investors will also maintain a significant interest in the downstream value creation from NEBIDO and the octreotide implant.

"Our employees, who have been so instrumental in the growth and success of Indevus, will also remain integral to the future of Endo," continued Dr. Cooper. "Our sales force, Cranbury operations, and the NEBIDO and Octreotide R&D teams are expected to play a very important role in the new Endo. In addition, Endo will look to our headquarters in Lexington, MA as a source of talent for their growing organization.

"Finally, we believe this transaction will create new value for our patients, physicians, and other customers under Endo's leadership. We believe Endo's proven commercial capabilities, targeted approach to medical marketing and unique understanding of the changes taking place in health care delivery today will ensure the success of our current and future products. We welcome and fully support this acquisition."

Transaction Terms

Under the terms of the agreement, Endo will commence a tender offer to purchase all outstanding shares of Indevus in exchange for an up-front payment of $4.50 in cash for each share of outstanding Indevus common stock ("Upfront Consideration"). In addition, Indevus shareholders will receive the non-transferrable contractual right to two contingent cash payments ("Contingent Cash Payments"), one for up to $2.00 per share and the other for $1.00 per share that could deliver up to an additional $267 million, or $3.00 per share in cash, if the Company meets certain targets.

The first Contingent Cash Payment relates to NEBIDO and is payable as follows: (i) $2.00 per share if NEBIDO is approved, within three (3) years of the closing of the tender offer, by the FDA for marketing and sale without certain restrictive labeling, or (ii) two potential payments in the event that NEBIDO is approved by the FDA with certain restrictive labeling, comprised of: (a) $1.00 per share upon such approval, if approval is obtained within three (3) years of the closing of the tender offer and (b) an additional $1.00 per share following the achievement of a certain sales threshold milestone during the first five (5) years from the date of the first commercial sale of NEBIDO.

The second Contingent Cash Payment relates to the octreotide implant and consists of $1.00 per share to be paid in the event that, within four (4) years of the closing of the tender offer, octreotide is approved by the FDA for marketing and sale for the treatment of acromegaly or carcinoid syndrome.

The tender offer is expected to commence within 5 days of the signing of the Merger Agreement and will remain open for 45 calendar days, subject to extension under certain circumstances. The tender offer closing is conditioned on the tender of a majority of the outstanding shares of Indevus' common stock, antitrust clearance and other customary closing conditions. The executive officers and directors of Indevus and certain of their affiliates, have agreed to tender approximately 4.7% of Indevus' outstanding shares in the tender offer.

UBS Securities LLC advised Indevus and provided a fairness opinion to Indevus' board of directors. Burns & Levinson LLP acted as legal counsel to Indevus.

Conference call and webcast

The live call may be accessed by dialing 800-561-2601 from the U.S. and Canada, and 617-614-3518 from international locations. The participant passcode is 42185623. Investors are advised to dial into the call at least ten minutes prior to the call to register. A replay of the call will be available beginning at 11:00 AM on January 6, 2009 and lasting until 12:00 AM on February 4, 2009. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 94686397.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, http://www.indevus.com/." target="_blank" rel="nofollow ugc noopener">http://www.indevus.com/. An archived version of the call will be accessible at the same web address for 30 days following the live call.

About NEBIDO(R)

NEBIDO is a long-acting depot preparation of testosterone undecanoate under development for the treatment of male hypogonadism. NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About Octreotide

The Indevus octreotide implant is a proprietary formulation of octreotide in a six-month implant utilizing the Company's patented HYDRON(R) Polymer Technology. The implant is inserted subcutaneously in the inner aspect of the upper arm and is specifically designed to provide a continuous release of octreotide, a long-acting octapeptide that mimics the natural hormone somatostatin to block release of growth hormone (GH), over a six-month period.

About Indevus Pharmaceuticals

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.

About Endo Pharmaceuticals

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, anesthesiology, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at http://www.endo.com/.

Forward Looking Statements

This press release contains information that includes or is based on "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on current expectations of future events. Also, statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may" or similar expressions are forward-looking statements. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Endo's and Indevus' expectations and projections. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of certain other regulatory approvals for the transaction, the tender of a majority of the outstanding shares of common stock of Indevus, and the possibility that the transaction will not be completed; general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Endo's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2007, filed with the U.S. Securities and Exchange Commission (SEC) on April 29, 2008, and its Quarterly Report on Form 10-Q/A for the fiscal quarter ended September 30, 2008, filed with the SEC on December 12, 2008 and Indevus' Form Annual Report on Form 10-K as filed with the SEC on December 11, 2008. Copies of these filings, as well as subsequent filings, are available online at http://www.sec.gov/, http://www.endo.com/, http://www.indevus.com/ or on request from Endo or Indevus. Neither Endo nor Indevus undertakes to update any forward-looking statements as a result of new information or future events or developments.

Additional Information

The tender offer described in this release has not yet commenced, and this release is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Endo will file a tender offer statement with the SEC. Investors and Indevus stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement that will be filed by Indevus with the SEC, because they will contain important information. These documents will be available at no charge on the SEC's website at http://www.sec.gov/. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge by directing a request to Endo at http://www.endo.com/, or Endo Pharmaceuticals, 100 Endo Boulevard, Chadds Ford, PA 19317, Attn: Corporate Secretary's Office.

Contact: Michael W. Rogers Robin L. DeCarlo EVP and Chief Financial Officer Sr. Director, Corporate Communications [phone] [phone]

DATASOURCE: Indevus Pharmaceuticals, Inc.

CONTACT: Michael W. Rogers, EVP and Chief Financial Officer,

[phone], or Robin L. DeCarlo, Sr. Director, Corporate Communications,

[phone]

Web Site: http://www.indevus.com/

[Bikermichel]

Das ist ja mal ein Umsatz heute.

Der Verkaufsdruck ist raus!
Meine Stücke sind noch nicht reif.

[Biotechspezialx]

Die schlagen vor der FDA Entscheidung zu!

Schöner Kurs Anstieg! Anders zwar gedacht wie es kommt .

Aber Geld ist Geld ... das läuft ja moementan wie geschmiert..

[Fallout-boy]

Kann mir mal einer erklären was "non-transferable contructual Right" bedeutet, hab heut von Cortal nen Brief bekommen zwecks der Übernahme von Endo. Da steht 4,50 USD /Aktie zzgl. non-transferable contructual Right welches Teilzahlungen von 3,00 USD beinhaltet. Soll das heißen das ich im Bestfall die Aktie zu 7,50 USD verkaufen kann... und im schlechtesten Fall mit 4,50 USD nach Hause gehe...Bin noch nen Rookie... THX im voraus

[Fallout-boy]

Alles klar..., hab den Übernahmetext mal übersetzt und gloobe ick weeß wat die meinen,... Teilzahlungen die fällig werden können nach Erfolg von de medikamente etc... Wünsch euch noch nen schnicken tach

[Daxterix]

Habe auch Indevus im Depot und überlege zu verkaufen. Weiß jemand, wie der doch relativ stabile Kurs von ca. 5,40 Dollar zustande kommt?
Wie schätzt Ihr die Chancen auf Kurssteigerungen bis zur FDA-Entscheidung ein?

Danke im Voraus!

[die_Mitte]

ich glaube , es können bei erfolgen zukünftiger medikamente noch
zahlungen von 3$ dazukommen.
also bei ca. us$ 8,50 ist schluss.
richtig?

[Bikermichel]

Chartanalyse (Quelle: Trading Central)
15.01. 14:00 Indevus Pharmaceuticals Inc : Technische Analyse

Kurzfristige(kfr.) Meinung: Kauf
Mittelfristige(mfr.) Meinung: Kauf
Veränderung
kfr.: Veränderung
mfr.:
Unterstützung: 2.65 / 4.15 / 4.74 Widerstand: 7.26 / 8.18 / 9.09

Unser Pivot-Punkt liegt bei 4.15.
Unsere Meinung: solange die Unterstützung bei 4.15 hält, ist die Aufwärtstendenz intakt.
Alternatives Szenario: unter 4.15 lauten die Kursziele 2.65 und 1.75
Analyse: der RSI liegt über 70. Das kann bedeuten, dass sich die Aktie entweder in einem anhaltenden Aufwärtstrend befindet oder dass sie überkauft ist und deshalb korrigieren wird (in diesem Fall auf bearishe Divergenzen achten). Der MACD liegt über der Signallinie und ist positiv. Die Konfiguration ist positiv.

[die_Mitte]

hallo leute.
habe heute post von der bank bekommen.
wer noch?
was machen wir nun?

im übernhame angebot steht nur schwammig drin , dass 3 weitere dollars nur fällig werden bei zulassung neuer medikamente und deren "erfolgreicher" absatz.
was soll das denn?
medikamente - bis wann?
nach der übernahme?
wie erfolgreich genau müssen die laufen?und wie lange?

ich glaube auf den ersten blick , es ist gesünder nicht einzureichen . oder?
das heisst , wenn weniger als 50,01% eingereicht werden.

stimmts?
wie seht ihr das?

einreichen oder nicht?
hat jemand weitere infos?

[Bikermichel]

Antwort auf Beitrag Nr.: 36.424.949 von die_Mitte am 22.01.09 10:39:47

Hallo,meine Frist ist seid dem 17.01.009 abgelaufen.
Habe ihn nicht in Anspruch genommen!
Glaube das hier noch ein bisschen mehr möglich ist.
Hab hier auch leider nicht die großen Stücke im Depot.
Ich laß hier einfach mal laufen
PS.Was man dir freiwillig gibt,ist in der Regel nicht das was es Wert ist.Schon gar nicht im Haifischbecken!
Aber jedem das seine.



Gruß Michel

[marcodo]

Ehrlich gesagt, kenne ich diese Aktie überhaupt nicht und melde mich heute hier zum ersten Mal. Aber auf einem Vortrag der DSW (Anlegerschutzorganisation) haben sie gesagt, dass in den USA eine Klage gegen den Laden angestrengt werden soll. Argumentation war in etwa so:

Aktionäre von Indevus haben (blabla )Grund, sich über die vor kurzem verkündete Übernahme durch den US-amerikanischen Wettbewerber Endo Pharmaceuticals zu sorgen. Indevus’ Aktionäre sollten einen besseren Übernahmepreis einfordern. Dies geht ohne Kosten oder Risiken. Der Übernahmepreis 3 Dollar pro Aktie niedriger, als er sein sollte. Bei diesen Kursen scheint es mir doch eine nette Besserung zu sein.

Der DSW-Mann bei dem Vortrag (Tüngler) hat gefragt, ob im Raum irgendwer Aktionär ist. Die suchen jemanden. Er meinte, dass der Kaufpreis zwar erst aufgebessert werden soll, wenn ein neues Indevus’ Medikament von der Gesundheitsbehörde FDA genehmigt wird. Er sagte aber auch, dass bereits jetzt alles darauf hindeutet, dass dies geschehen wird, so dass der Übernahmepreis bereits jetzt aufgebessert werden sollte.

Ich beglückwünsche denjenigen, der Aktien des Ladens hat! Aber: Man muss sich bei der DSW melden und eine offenbar kostenlose und risikolose Klage anstrengen. Tüngler meinte, dass die DSW das für Anleger macht. Also: Meldet Euch, wenn Ihr Aktionäre seid. Den Kontakt könnt Ihr über die DSW-Seite herstellen

[e-mail]

[die_Mitte]

Hi.
Danke Dir !

Seh ich auch so.
mindestens 3 dollarchens zu niedrig.

Noch wer an board?

[Bikermichel]

Results of NIH-sponsored Clinical Trial to be Presented at Retrovirus Conference

LEXINGTON, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced today that a National Institutes of Health (NIH)-sponsored clinical study found that participating women who received PRO 2000, the Company's candidate vaginal microbicide for HIV prevention, had an approximately 30% lower risk of acquiring HIV infection than women who received a placebo or no vaginal product. All women participating in the study were offered free condoms and safer-sex counseling. This is the first trial to suggest any microbicide may prevent male-to-female sexual transmission of HIV although the beneficial effect did not reach statistical significance. The results will be presented today at the 16th Conference on Retroviruses and Opportunistic Infections in Montreal.

"We are extremely excited with the results of this trial," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "Though not conclusive, these results provide encouragement that PRO 2000 may offer a female-controlled method that can be used to protect against the sexual transmission of HIV.

"In addition to the HPTN 035 trial, we are awaiting results from the MRC-sponsored trial which will provide data on nearly 10,000 women," continued Dr. Cooper. "These results should be available by the end of 2009."

The HIV Prevention Trials Network (HPTN) 035 trial was a multi-national, randomized, placebo-controlled trial to assess the safety and effectiveness of PRO 2000 and another investigational vaginal microbicide (BufferGel(R), ReProtect, Inc.) in preventing HIV infection in women. The trial was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the NIH, and conducted by the NIH-funded Microbicide Trials Network (MTN) at seven clinical centers in Malawi, Zimbabwe, South Africa, Zambia, and the United States.

The trial was initiated in February 2005 and enrolled approximately 3,100 eligible, HIV-uninfected women, all of whom provided written informed consent. Enrolled participants were randomly assigned to one of four arms: PRO 2000 gel (0.5% strength), BufferGel, a placebo gel, or no gel. Women enrolled in the three gel arms were asked to apply the assigned study product vaginally up to one hour before each act of sexual intercourse. The gel arms were double-blinded so that neither the participant nor the study staff knew the identity of the assigned study product. Women in all four arms received a standard-of-care HIV prevention package, which included free male condoms, risk-reduction counseling, and treatment of sexually transmitted infections. Participants were followed for 12-30 months (20 months on average), depending on when they entered the study.

A total of 194 new HIV infections occurred among study participants over the course of the trial. Of these, 36 occurred in the PRO 2000 arm, 54 in the BufferGel arm, 51 in the placebo arm, and 53 in the no-gel arm. Based on these data, PRO 2000 was 30 percent effective (approximately 33 percent effectiveness would have been considered statistically significant). The adverse event profile was similar in all four arms, indicating that 0.5% PRO 2000 is safe for vaginal use. A full analysis of the trial data is underway.

The study was conducted in communities where the background rate of HIV infection is high. Participants who became infected with HIV during the trial were referred to local HIV care and support services. Where possible, infected participants were invited to participate in Microbicide Trials Network (MTN) 015, a clinical study examining the nature of HIV progression and treatment response in HIV-positive women who had been using a topical microbicide or oral antiretrovirals as an HIV preventive measure when they acquired HIV infection.

A second large trial testing the safety and effectiveness of the 0.5% dose of PRO 2000 is currently underway. This trial is being sponsored by the United Kingdom's Medical Research Council (MRC) and conducted by the Microbicides Development Programme (MDP), an international partnership of researchers established to develop microbicides for the prevention of HIV transmission. Study MDP 301 is a multi-national, randomized, double-blind, placebo-controlled Phase III trial designed to examine the safety and effectiveness of PRO 2000 in preventing HIV infection in women. As in the HPTN 035 trial, all participants receive free condoms, risk-reduction counseling, and treatment for sexually transmitted infections. Approximately 9,400 women have been enrolled at study sites in South Africa, Tanzania, Uganda, and Zambia. The trial is expected to be completed during the summer of 2009.

Should PRO 2000 be shown conclusively to be safe and effective, Indevus intends to seek worldwide marketing approvals, and plans to work with government agencies and other organizations to help ensure affordable access to the product in resource-limited settings where the need is greatest.

According to statistics from UNAIDS and the U.S. Centers for Disease Control and Prevention, nearly half of the 33 million people living with HIV/AIDS worldwide are women. Most HIV infections in women are due to heterosexual intercourse. Moreover, women are twice as likely as their male partners to acquire HIV during sex, due in part to biological factors that make women more vulnerable. Although correct and consistent use of male condoms has been shown to prevent HIV infection, women often cannot negotiate condom use with their male partners. A safe and effective vaginal microbicide could offer a readily available approach for many women who cannot simply rely on condoms or abstinence as methods for protecting themselves from HIV. Even a partially effective microbicide could have a profound impact on the dynamics of HIV transmission. According to mathematical modeling conducted by the London School of Hygiene and Tropical Medicine, 2.5 million HIV infections could be averted over three years if a microbicide with 60 percent effectiveness were used in 73 low-income countries.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.

PRO 2000

PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal microbicide to prevent the sexual transmission of HIV and other sexually transmitted diseases. Laboratory studies have shown that PRO 2000 is active against HIV, herpes simplex virus, chlamydia and the bacterium that causes gonorrhea. Vaginally applied PRO 2000 has been found to afford protection in mouse models for genital herpes infection and gonorrhea, and in a simian model for vaginal HIV infection. Prior to initiation of the HPTN 035 trial, PRO 2000 had undergone extensive safety testing in several clinical trials involving women and men in the United States, Europe, Africa and India.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR(TM); reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Michael W. Rogers Robin L. DeCarlo EVP and Chief Financial Officer Sr. Director, Corporate Communications [phone] [phone]

DATASOURCE: Indevus Pharmaceuticals, Inc.

CONTACT: Michael W. Rogers, EVP and Chief Financial Officer,

[phone]; Robin L. DeCarlo, Sr. Director, Corporate Communications,

[phone], both of Indevus Pharmaceuticals, Inc.

[Bikermichel]

Die BTP Purchaser Inc.eine direkte Tochtergesellschaft der Endo
Pharmaceuticals Holdings Inc.,bietet Ihnen als Aktionär........
Frist:09.02.009-20.02.009 (wurde verlängert)

Hallo,kommt sicher einigen bekannt vor.
Das billig einsammeln läuft wohl nicht so richtig:
Für den aktuellen Endo Kurs können sie meine haben.

[die_Mitte]

infektionsgefahr 30% geringer mit pro 2000?

richtig?


sorry , wie lange verlängert?

[die_Mitte]

bis 20.2?

[Bikermichel]

Antwort auf Beitrag Nr.: 36.544.339 von die_Mitte am 09.02.09 20:09:42

Hallo
PRO 2000 (naphthalin sulfonat Polymer) ist in der Entwicklung als ein aktuelles vaginalen Mikrobiziden zur Verhinderung der sexuellen Übertragung von HIV und anderen sexuell übertragbaren Krankheiten. Labor-Untersuchungen haben gezeigt, dass Pro 2000 ist wirksam gegen HIV, Herpes-simplex-Viren, Chlamydien und das Bakterium, das Gonorrhoe. Vaginal angewandt PRO 2000 wurde festgestellt, schützt in Maus-Modellen für den Genital-Herpes-Infektionen und Gonorrhö, und in einem Simian für vaginale HIV-Infektion. Vor der Einleitung der Studie HPTN 035, PRO 2000 hatte eine umfassende Sicherheits-Tests in mehreren klinischen Studien mit Frauen und Männern in den Vereinigten Staaten, Europa, Afrika und Indien.

Ja,30% geringer lese ich auch daraus.(gesammte Meldung)
Egal,"Wir sind sehr begeistert mit den Ergebnissen dieser Studie", erklärte Glenn L. Cooper, MD, Vorsitzender und Chief Executive Officer von Indevus.

Na, dann sind wir doch auch begeistert.

Und Frist bis 20 Februar verlängert.(vorläufig!?)

FDA zu Nebido kommt ja auch noch!
Kommt bestimmt wenn die Frist abgelaufen ist (nur so eine Vermutung

[Bikermichel]

Nas -3,4%
Dow -4,2%


An Indevus geht das im Moment alles vorbei

[Daxterix]

Antwort auf Beitrag Nr.: 36.552.534 von Bikermichel am 10.02.09 20:06:34

Hi,

weiß jemand, wie das Verfahren nach Ablauf der Frist aussieht?
- erforderliche Aktienanzahl für Übernahme erreicht
- reicht nicht
was ist in diesen Fällen mit den eigenen Aktien, wenn man dem Übernahmeangebot nicht zugestimmt hat?

Zudem habe ich gelesen, dass wohl eine Aktionärsklage wegen des geringen Übernahmepreises pro Aktie anhängig sein soll. Habt ihr hier was gehört? Muss man sich aktiv dranhängen?

Gruß an alle Abwartenden
Daxterix

[die_Mitte]

fette pakete im ask.
wasn los?

gruß

[die_Mitte]

war wohl ne falle.

jetzt fette pakete im bid und besitzer gewechselt.

da kaufen wohl einige dick ein?

gut , das wir noch welche behalten haben.

wer ist noch an board?

[Bikermichel]

AmericanBulls.com

BUY-IF

5,5500
+0,0400 +0,73%
Candlestick-Analyse
Die heutige Candlestick-Muster:
White Eröffnung Marubozu
Bullish drei weißen Soldaten

Candlestick-Muster

Heute ist ein White Eröffnung Marubozu wurde. Dies zeigt, dass der Tag geöffnet und dann die Preise weiter nach oben den ganzen Tag lang, ohne unter die Öffnung Ebene und bilden somit einen langen weißen Körper, aber die Preise nicht in unmittelbarer Nähe die hohe des Tages und damit sie einen oberen Schatten.


Die letzten drei Leuchter ein Bullish drei weißen Soldaten Muster. Dies ist eine Umkehrung auf ein bullish Muster, markiert den Beginn einer möglichen Veränderung im Trend.
Hm,der Trend war doch garnicht mal so übel

Die drei werden`s schon richten

[Bikermichel]

Na also,prima Volumen u.einen netten Endspurt.

So kann es weiter gehen,immer schön in Richtung Endo.

[die_Mitte]

na , das nenn ich doch mal big blocks.

wie hoch gehts?
was meint ihr?

[Bikermichel]

Hallo,
Übersetzung: Englisch » Deutsch
27.02.2009 23:58 UPDATE 1-Indevus gets FDA nod to reintroduce cancer therapy * Says FDA approved sNDA for Valstar * Plans to market Valstar in H2 2009 * Shares up 5 pct Feb 27 (Reuters) - Indevus Pharmaceuticals Inc (News) received marketing approval from U.S. health regulators for its cancer therapy Valstar, which was withdrawn in 2002 due to impurities in the original formulation. Shares of the company rose 5 percent after the bell. Indevus said in a regulatory filing that it obtained approval from the U.S. Food and Drug Administration on its supplemental new drug application for Valstar. The company, which agreed to be bought by Endo Pharmaceuticals Inc for $370 million last month, plans to market Valstar during the second half of 2009. Valstar was approved in 1998 as a treatment for bladder cancer in patients who were not candidates for bladder removal. Shares of the company were up at $5.35 in trading after the bell. They closed at $5.11 Friday on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Himani Sarkar) Keywords: INDEVUS/ ([e-mail]; within U.S. [phone]; outside U.S. [phone]; Reuters Messaging: [e-mail]) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
27.02.2009 23:58
UPDATE 1-Indevus erhält FDA nod die Wiedereinführung der Krebstherapie
Google-deutsch geht doch
* Says FDA genehmigt sNDA für Valstar

* Pläne auf den Markt Valstar in H2 2009

* Aktien um 5 pct

27. Feb (Reuters) - Indevus Pharmaceuticals Inc (News) erhalten Zulassung von US-Regulierungsbehörden für die Gesundheit ihrer Krebstherapie Valstar, die wurde im Jahr 2002 durch Verunreinigungen in der ursprünglichen Formulierung.

Aktien der Gesellschaft erhöhte sich 5 Prozent, nachdem die Glocke.

Indevus in einem regulatorischen Einreichung, dass sie die Erlaubnis von der US Food and Drug Administration über seine zusätzliche New Drug Application für Valstar.

Das Unternehmen, das sich zu kaufen von Endo Pharmaceuticals Inc für $ 370 Mio. im letzten Monat, Pläne auf den Markt Valstar in der zweiten Hälfte des Jahres 2009.

Valstar wurde in 1998 als Behandlung für Blasenkrebs bei Patienten, die nicht Kandidaten für die Entfernung der Blase.

Aktien des Unternehmens waren bis auf $ 5,35 in den Handel, nachdem die Glocke. Sie wird um $ 5,11 Freitag an der Nasdaq.

(Berichterstattung durch die Vidya L Nathan in Bangalore; Bearbeitung von Himani Sarkar) Stichworte: INDEVUS /

(vidya.loganathan @ thomsonreuters.com; den USA [phone], außerhalb der USA [phone], Reuters Messaging: vidya.loganathan.reuters.com @ Reuters.Net)

[Bikermichel]

Kleiner Rückblick
Lexington, Mass, Aug. 17.2007 / Update wird - Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) gab heute bekannt, dass sie hat einen genehmigungsfähigen Schreiben von der US Food and Drug Administration (FDA) für Valstar (R). Valstar, einer sterilen Lösung von valrubicin für intravesical Instillation, ist das einzige Produkt von der FDA für die Therapie von Bacillus Calmette-Guerin (BCG)-refraktären Karzinom in situ (CIS) der Harnblase.

Valstar wurde aus dem Markt im Jahr 2002 durch Verunreinigungen in der ursprünglichen Formulierung und wurde auf der FDA Drug Mangel Liste. Indevus löste das Problem und Unreinheit einen Chemie, Herstellung und Kontrollen (CMC) NDA Ergänzung der FDA im Mai 2007. Die FDA genehmigungsfähigen Schreiben wurde als Antwort auf diese Chemie ergänzen.

In der genehmigungsfähigen Schreiben hat die FDA um eine Klarstellung gebeten in Bezug auf Herstellung und Validierung Protokolle für zusätzliche Daten über den Herstellungsprozess.

"Valstar bietet eine wirksame Alternative für Patienten mit Blasenkrebs haben nicht BCG-Therapie und sind keine Kandidaten für den sofortigen cystectomy", erklärte Glenn L. Cooper, MD, Vorsitzender und Chief Executive Officer von Indevus. "Die FDA fordert in der genehmigungsfähigen Schreiben adressierbar sind leicht mit den bestehenden Daten und die Übergabe von ein paar kurzen Prozess im Zusammenhang Ermittlungen. Wir erwarten die Lieferung der FDA mit einem kompletten binnen der nächsten zwei Monate. Wir sind nach wie vor auf dem richtigen Weg für eine Ende 2007 oder Anfang 2008 wieder-Einführung. "


Genehmigung kommt etwas Später als gedacht. Kann mir nicht vorstellen,das damit jemand gerechnet hat.Warten doch alle nur auf Nebido.Bin mal gespannt wie das hier weiter geht.

[Hase3]

Hat noch jemand Indevus-Aktien ? Wo kann man die noch handeln ? Habe die Kaufofferte von Endo nicht angenommen.

[Daxterix]

Antwort auf Beitrag Nr.: 36.847.389 von Hase3 am 25.03.09 19:40:27

Habe auch noch Indevus-Aktien. Sind vom Handel ausgesetzt. Gehe davon aus, dass man jetzt nur noch zu 4,50 Dollar verkaufen, und in Zukunft auf (einen Teil) der zusätzlichen 3 Dollar on top hoffen kann.
Oder weiß jemand näheres?

[derhellste]

Habe auch noch die Aktien behalten und habe über Sammelklage in den USA versucht ein höheres Angebot zu erhalten. Das Ergebnis steht noch aus.
Problem ist auch, dass bei einer 4,50$-Annahme nach US-Recht die volle Summe steuerpflichtig ist, eine 1-Jahresregel (altes deutsches Recht da Kauf in 2008) nicht greift bzw. auch aufgrund der vorzeitigen Abwicklung selbt diese Frist nicht wirkt. Die Nachbesserung von bis zu 3Doller ist dann auch nochmal spannend.
Vor 2 Wochen erhielt ich ein Schreiben über die depotführende Bank, dass in kürze die 4,5$ bezahlt werden sollen.
Hat jemand ein ähnliches Schreiben erhalten? Haben weitere User Klage eingereicht?
Ist hier überhaupt noch jemand oder haben sich alle verabschiedet?

[Hase3]

Habe noch ein paar Indevus-Aktien, weiß aber auch nicht, wie ich damit umgehen soll. Die Comdirectbank als depotführende Bank hat mir auch kein Schreiben zukommen lassen, in dem von einer bevorstehenden Auszahlung die Rede wäre.
Allerdings habe ich auf der Homepage von Endo (www.endo.com) eine Meldung zu einem Angebot gefunden, das wohl am 22.4.09 abläuft. Leider kann ich Englisch nicht gut genug, als das ich das genau übersetzen könnte. Vielleicht kann es ja mal jemand versuchen.

[Daxterix]

Antwort auf Beitrag Nr.: 37.022.166 von Hase3 am 22.04.09 22:53:21

Hallo,
habe die 4,50 Dollar mittlerweile (in Euro) auf dem Konto und das Nachbesserungsrecht auf die 2-3 Dollar (wer weiß wann...).
Über die Sammelklage habe ich es nicht versucht (wußte auch nichts konkretes), wünsche aber hier den Klägern viel Erfolg!